Literature DB >> 28325572

Lipid profile disturbances in antipsychotic-naive patients with first-episode non-affective psychosis: A systematic review and meta-analysis.

Błażej Misiak1, Bartłomiej Stańczykiewicz2, Łukasz Łaczmański3, Dorota Frydecka2.   

Abstract

BACKGROUND: Dyslipidaemia is one of the most prevalent metabolic disturbances observed in schizophrenia patients and has been largely attributed to the effects of poor lifestyle habits and adverse effects of antipsychotic treatment. However, less is known whether patients with first-episode non-affective psychosis (FENP) present subthreshold indices of dyslipidaemia. Therefore, we tested the hypothesis whether subclinical lipid profile alterations occur already in antipsychotic-naïve FENP patients.
METHODS: In this systematic review and meta-analysis we adhered to the PRISMA guidelines and searched PubMed, CINAHL Complete, Academic Search Complete, ERIC and Health Source: Nursing/Academic Edition from database inception to Dec 12, 2016, for case-control studies measuring the levels of total cholesterol, low- and high-density lipoproteins (LDL and HDL) and triglycerides in patients with FENP and controls. W calculated effect size (ES) estimates as Hedges' g and pooled data using random- or fixed-effects models depending on heterogeneity. Our study was registered in the PROSPERO database (CRD42016051732).
RESULTS: Out of 2466 records identified, 19 studies representing 1803 participants were finally included in our systematic review and meta-analysis. Pooled analysis revealed that FENP patients had significantly lower levels of total cholesterol [ES=-0.16 (95% CI: -0.27, -0.06), p=0.003], LDL [ES=-0.13 (95% CI: -0.24, -0.01), p=0.034] and HDL [ES=-0.27 (95% CI: -0.49, -0.05), p=0.018] as well as significantly higher levels of triglycerides [ES=0.22 (95% CI: 0.11, 0.32), p<0.001] compared to controls. After removing single studies in sensitivity analysis, ES estimate for LDL levels was insignificant.
CONCLUSIONS: Antipsychotic-naïve patients with FENP present subclinical dyslipidaemia. Future studies should disentangle whether our findings reflect disease-specific mechanisms.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholesterol; Lipids; Lipoproteins; Metabolic dysregulation; Psychotic disorders; Schizophrenia

Mesh:

Substances:

Year:  2017        PMID: 28325572     DOI: 10.1016/j.schres.2017.03.031

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  25 in total

1.  Physical Illnesses Before Diagnosed as Schizophrenia: A Nationwide Case-Control Study.

Authors:  Yi-Lung Chen; Chun-Hung Pan; Chi-Kang Chang; Pao-Huan Chen; Hu-Ming Chang; Ming-Hong Tai; Sheng-Shiang Su; Shang-Ying Tsai; Chiao-Chicy Chen; Chian-Jue Kuo
Journal:  Schizophr Bull       Date:  2020-07-08       Impact factor: 9.306

2.  Plasma linoelaidyl carnitine levels positively correlated with symptom improvement in olanzapine-treated first-episode drug-naïve schizophrenia.

Authors:  Xuan Wang; Meihong Xiu; Keqiang Wang; Xiuru Su; Xirong Li; Fengchun Wu
Journal:  Metabolomics       Date:  2022-07-11       Impact factor: 4.747

3.  Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis.

Authors:  Liisa Leppik; Madis Parksepp; Sven Janno; Kati Koido; Liina Haring; Eero Vasar; Mihkel Zilmer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-01-02       Impact factor: 5.270

Review 4.  Roles of inflammation in intrinsic pathophysiology and antipsychotic drug-induced metabolic disturbances of schizophrenia.

Authors:  Tyler R Prestwood; Roshanak Asgariroozbehani; Sally Wu; Sri Mahavir Agarwal; Ryan W Logan; Jacob S Ballon; Margaret K Hahn; Zachary Freyberg
Journal:  Behav Brain Res       Date:  2021-01-14       Impact factor: 3.332

5.  Development and external validation of the Psychosis Metabolic Risk Calculator (PsyMetRiC): a cardiometabolic risk prediction algorithm for young people with psychosis.

Authors:  Benjamin I Perry; Emanuele F Osimo; Rachel Upthegrove; Pavan K Mallikarjun; Jessica Yorke; Jan Stochl; Jesus Perez; Stan Zammit; Oliver Howes; Peter B Jones; Golam M Khandaker
Journal:  Lancet Psychiatry       Date:  2021-06-01       Impact factor: 27.083

6.  Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia.

Authors:  Zachary Freyberg; Despoina Aslanoglou; Ripal Shah; Jacob S Ballon
Journal:  Front Neurosci       Date:  2017-07-28       Impact factor: 4.677

7.  Serum fatty acid patterns in patients with schizophrenia: a targeted metabonomics study.

Authors:  X Yang; L Sun; A Zhao; X Hu; Y Qing; J Jiang; C Yang; T Xu; P Wang; J Liu; J Zhang; L He; W Jia; C Wan
Journal:  Transl Psychiatry       Date:  2017-07-25       Impact factor: 6.222

8.  Blood-Based Lipidomics Approach to Evaluate Biomarkers Associated With Response to Olanzapine, Risperidone, and Quetiapine Treatment in Schizophrenia Patients.

Authors:  Adriano Aquino; Guilherme L Alexandrino; Paul C Guest; Fabio Augusto; Alexandre F Gomes; Michael Murgu; Johann Steiner; Daniel Martins-de-Souza
Journal:  Front Psychiatry       Date:  2018-05-25       Impact factor: 4.157

9.  Ubiquitin-proteasome system, lipid metabolism and DNA damage repair are triggered by antipsychotic medication in human oligodendrocytes: implications in schizophrenia.

Authors:  Gabriela Seabra; Valéria de Almeida; Guilherme Reis-de-Oliveira; Fernanda Crunfli; André Saraiva Leão Marcelo Antunes; Daniel Martins-de-Souza
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

10.  Unveiling the Metabolic Profile of First-Episode Drug-Naïve Schizophrenia Patients: Baseline Characteristics of a Longitudinal Study Among Han Chinese.

Authors:  Qi Zhang; Hui He; Xia Bai; Liping Jiang; Wei Chen; Xiaoying Zeng; Yanjia Li; Antonio L Teixeira; Jing Dai
Journal:  Front Psychiatry       Date:  2021-07-09       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.